Australian medical company 4DMedical reported on Monday the receipt of clearance from the US Food & Drug Administration to market its XV Technology that rapidly and automatically analyses any functional lung impairment including COVID-19 from a single X-ray.
A patented four-dimensional lung imaging process, the XV Technology provides critical information about the functional and structural state of a patient's lungs in the treatment of illnesses including COVID-19, asthma, chronic obstructive pulmonary disease, cystic fibrosis as well as lung cancer, added the company.
The company said the XV Technology process is a software-as-a-service (SaaS) diagnostic tool, available through secure cloud subscription, and can be implemented immediately, utilizing existing hospital and clinical infrastructure with no capital expenditure or training required.
According to the company, the software generates a ventilation report within three hours and sends it to the hospital to enable clinicians to determine the most effective treatment course of action and allocation of finite hospital resources. The technology is supported by 15 years of preclinical and clinical trials and ongoing collaborations with leading hospitals worldwide.
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
QST selects RayStation for advanced carbon ion therapy
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development